Aug 13, 2026 earnings call — Shift to provider-targeted commercial strategy
Shift to provider-targeted execution and H2 2026 SG&A and R&D set at $114 million-$126 million.
Revenue $0.0B (est $0.0B) · EPS $-0.63 (est $-0.48)
Key quotes
"We are prioritizing our resources and focus where they make the greatest immediate impact on neffy market share, the healthcare provider."
"To give a clear baseline for our future runway, we've adjusted our aggregate SG&A and R&D expenses for the second half of 2026 to be in the range of $114 million-$126 million, which includes stock-based compensation of about $14 million-$16 million."
"Given the real-world time required for patients to complete all three episodes for valid data collection, the interim readout is now expected in Q1 2027."
Analyst Q&A 5
gross-to-net, margins, and field sales share
Q (Josh Schimmer · Cantor Fitzgerald): They asked how gross-to-net and product margins behaved this quarter and what drove the cost-of-goods increase. They also asked how the company plans to raise the 8% penetration in field-targeted accounts.
A: They expect gross-to-net to ebb and flow by segment but are comfortable around 50% and with it for cash-flow break-even. Gross margin was lower this quarter (about 62% in Q2, a little over 64% year-to-date) due to short-dated product reserves, manufacturing inefficiencies scaling, and ex-U.S. launch costs; they expect margins to improve into 2027 as manufacturing streamlines. For field-targeted accounts, the expanded sales team is fully deployed and they will use provider-targeted messaging and provider-by-provider execution to grow share.
"Our gross margin was about, excuse me, 62% in Q2 and a little over 64% year-to-date." — Kathy Scott (CFO)
payer access and DTC strategy changes
Q (Ryan Deschner · Raymond James): He asked how payer access will progress and how critical Caremark formulary inclusion is. He also asked for specifics on the new DTC strategy: channels, media, and spend versus the prior approach.
A: They will keep working to reduce friction and improve access, but say provider conviction is the critical next step even with current coverage levels. Coverage is currently 90% commercial and 57% without a prior authorization; they have shifted strategy from activating consumers to activating providers to be more efficient. DTC will move away from broad linear TV to more efficient channels like social and search, and will use targeted channels for providers as well to reduce SG&A.
"There is coverage currently, 90% commercial coverage, 57% without a prior authorization." — Donn Casale (CEO)
no follow-up question (brief closing)
Q (Ryan Deschner · Raymond James): The analyst offered thanks and had no new question.
A: Management did not provide new substantive information in this exchange; they simply closed the call with appreciation. No operational or financial details were discussed here.
"Thank you, Ryan." — Donn Casale (CEO)
path to cash-flow breakeven and back-to-school
Q (Roanna Ruiz · Leerink Partners): She asked for the path and assumptions to reach cash-flow breakeven into 2027 and whether back-to-school is a tailwind. She also asked what provider habits they plan to change and how the field force will educate.
A: They are comfortable with breakeven driven largely by much more efficient SG&A spend; SG&A was reduced by over 40% from the first semester to the second semester and that efficiency trend continues through 2027. They expect continued revenue and market-share gains to support profitability. On back-to-school, Q3 has higher volume but the strategy (engaging providers and driving conviction) stays the same; to change provider habits they will use frequent, targeted messaging to physicians, nurses, and MAs and a methodical provider-by-provider field effort.
"As we shared, our SG&A was reduced by over 40% from the first semester to the second semester." — Donn Casale (CEO)
prescriber metrics and July license deal
Q (Lachlan Hanbury-Brown · William Blair): He asked what interim prescriber-engagement metrics they can track besides scripts, and asked about the July license agreement and whether it expands the pipeline.
A: Scripts and market share are the best indicators, but they will also track activity, frequency, and multiple calls per office (physician, nurse, MA) to see what drives scripts. They already see that deploying the field team changes share (8% where targeted vs 1% where not), and the July license gives potential line-extension opportunities for the pipeline though it is too early to comment further.
"As I said in the prepared remarks, we have 8% share in that total field-targeted universe versus a 1% share where we don't send our team." — Donn Casale (CEO)